Inl Med - Endcrn Diabetes Clin

Medicine & Life Sciences

1. Insulin 100%
2. Type 2 Diabetes Mellitus 78%
3. Type 1 Diabetes Mellitus 72%
4. Glucose 36%
5. Metformin 31%
6. Diabetes Complications 25%
7. Placebos 25%
8. Therapeutics 22%
9. Subcutaneous Infusions 21%
10. Hyperglycemia 20%
11. Diabetes Mellitus 19%
12. insulin aspart, insulin aspart protamine drug combination 30:70 18%
13. Glucagon 17%
14. Glycated Hemoglobin A 16%
15. Diabetic Neuropathies 15%
16. Insulin Resistance 15%
17. Fasting 14%
18. repaglinide 14%
19. Meals 14%
20. Blood Glucose 13%
21. Carvedilol 13%
22. Hypertension 13%
23. Insulin Glargine 13%
24. Aldehyde Reductase 12%
25. Blood Pressure 12%
26. Hypoglycemia 11%
27. C-Peptide 11%
28. Basement Membrane 11%
29. Metoprolol 10%
30. Safety 10%
31. Insulin Aspart 10%
32. Diabetic Nephropathies 9%
33. Hypoglycemic Agents 9%
34. Diabetic Retinopathy 9%
35. Rosiglitazone 9%
36. Hemoglobins 8%
37. Weight Gain 8%
38. Prediabetic State 8%
39. Injections 8%
40. Insulin Lispro 8%
41. Kidney 7%
42. Hyperinsulinism 7%
43. Somatostatin 7%
44. Cardiovascular Diseases 7%
45. Clinical Trials 7%
46. Peripheral Nervous System Diseases 7%
47. methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate 6%
48. Troglitazone 6%
49. Biphasic Insulins 6%
50. Antihypertensive Agents 6%
51. Pioglitazone 6%
52. Thiazolidinediones 6%
53. Epidemiology 6%
54. Erythrocytes 6%
55. Lipoproteins 6%
56. Multicenter Studies 6%
57. Ergocalciferols 6%
58. very low density lipoprotein triglyceride 5%
59. Hypertriglyceridemia 5%
60. Insulin Receptor 5%
61. Abatacept 5%
62. Skeletal Muscle 5%
63. Infusion Pumps 5%
64. Liraglutide 5%
65. Insulin Secretion 5%
66. Liver 5%